______________________________________________________________________________________________________________________________________________________________________________________________________
2011:
Mester G, Hoffmann V, Stevanovic S (2011) Insights into MHC class I antigen processing gained from large-scale analysis of class I ligands. Cell Mol Life Sci 68:1521-1532
2009:
Klug F, Miller M, Schmidt HH, Stevanovic S (2009) Characterization of MHC ligands for peptide based tumor vaccination. Curr Pharm Des 15:3221-3236
2007:
Schuler MM, Nastke MD, Stevanovic S (2007) SYFPEITHI: Database for searching and T cell epitope prediction. Methods Mol Biol 409:75-93
Gouttefangeas C, Stenzl A, Stevanovic S, Rammensee HG (2007) Immunotherapy of renal cell carcinoma. Cancer Immunol Immunother 56:117-128
2006:
Weinzierl AO, Stevanovic S (2006) LC-MS-based protein and peptide quantification using stable isotope labels. Biotechnol Gen E Rev 23:21-39
Dengjel J, Stevanovic S (2006) Naturally presented MHC ligands carrying glycans. Transfus Med Hemother 33:38-44
Hillen N, Stevanovic S (2006) Contribution of mass spectrometry-based proteomics to immunology. Expert Rev Proteomics 3:653-664
Schmid D, Dengjel J, Schoor O, Stevanovic S, Münz C (2006) Autophagy in innate and adaptive immunity against intracellular pathogens. J Mol Med 28:1-9
2005:
Stevanovic S (2005) Antigen processing is predictable: From genes to T cell epitopes. Transpl Immunol 14:171-174
Dengjel J, Rammensee HG, Stevanovic S (2005) Glycan side chains on naturally presented MHC class II ligands. J Mass Spectrom 40:100-104
2003:
Stevanovic S, Lemmel C, Häntschel M, Eberle U (2003) Generating data for databases--the peptide repertoire of HLA molecules. Novartis Found Symp 254:143-155
Lemmel C, Stevanovic S (2003) The use of HPLC-MS in T-cell epitope identification. Methods 29:248-259
2002:
Rammensee HG, Weinschenk T, Gouttefangeas C, Stevanovic S (2002) Towards patient-specific tumor antigen selection for vaccination. Immunol Rev 188:164-176
Stevanovic S (2002) Structural basis of immunogenicity. Transpl Immunol 10:133-136
Stevanovic S (2002) Identification of tumour-associated T-cell epitopes for vaccine development. Nature Rev Cancer 2:514-520
2001:
Schirle M, Weinschenk T, Stevanovic S (2001) Combining computer algorithms with experimental approaches permits the rapid and accurate identification of T cell epitopes from defined antigens. J Immunol Methods 257:1-16
1999:
Stevanovic S, Schild H (1999) Quantitative aspects of T cell activation: Peptide generation and editing by MHC class I molecules. Sem Immunol 11:375-384
Kanz L, Brossart P, Stuhler G, Reichardt V, Kleihauer A, Scheding S, Stevanovic S, Einsele H, Rammensee HG, Brugger W (1999) Pre-clinical and early clinical experience using dendritic cells to treat human malignancy. Hematol Cell Ther 41:56-57
Münz C, Nickolaus P, Lammert E, Pascolo S, Stevanovic S, Rammensee HG (1999) The role of peptide presentation in the physiological function of HLA-G. Sem Cancer Biol 9:47-54
1995:
Stevanovic S, Pomer S, Rammensee HG (1995) Oberflächenantigene im Nierenzellkarzinom - Präsentation von MHC I-gebundenen Selbstpeptiden. Akt Urol 26:S45-S46
1994:
Stevanovic S, Rammensee HG (1994) Identification of T-cell epitopes using allele-specific ligand motifs. Behring Inst Mitt 95:7-13
1993:
Stevanovic S, Wiesmüller KH, Metzger J, Beck-Sickinger AG, Jung G (1993) Natural and synthetic peptide pools: characterization by sequencing and electrospray mass spectrometry. BioMed Chem Lett 3:431-436